111 related articles for article (PubMed ID: 32892640)
21. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).
Palmioli A; Sacco E; Airoldi C; Di Nicolantonio F; D'Urzo A; Shirasawa S; Sasazuki T; Di Domizio A; De Gioia L; Martegani E; Bardelli A; Peri F; Vanoni M
Biochem Biophys Res Commun; 2009 Sep; 386(4):593-7. PubMed ID: 19540195
[TBL] [Abstract][Full Text] [Related]
22. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
[TBL] [Abstract][Full Text] [Related]
23. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
24. Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence.
Vo U; Vajpai N; Flavell L; Bobby R; Breeze AL; Embrey KJ; Golovanov AP
J Biol Chem; 2016 Jan; 291(4):1703-1718. PubMed ID: 26565026
[TBL] [Abstract][Full Text] [Related]
25. Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy.
Kraulis PJ; Domaille PJ; Campbell-Burk SL; Van Aken T; Laue ED
Biochemistry; 1994 Mar; 33(12):3515-31. PubMed ID: 8142349
[TBL] [Abstract][Full Text] [Related]
26. Conformation of the Ras-binding domain of Raf studied by molecular dynamics and free energy simulations.
Zeng J; Treutlein HR; Simonson T
Proteins; 1998 May; 31(2):186-200. PubMed ID: 9593192
[TBL] [Abstract][Full Text] [Related]
27. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.
Shima F; Yoshikawa Y; Matsumoto S; Kataoka T
Enzymes; 2013; 34 Pt. B():1-23. PubMed ID: 25034098
[TBL] [Abstract][Full Text] [Related]
28. A new concept for glycosyltransferase inhibitors: nonionic mimics of the nucleotide donor of the human blood group B galactosyltransferase.
Schaefer K; Albers J; Sindhuwinata N; Peters T; Meyer B
Chembiochem; 2012 Feb; 13(3):443-50. PubMed ID: 22223604
[TBL] [Abstract][Full Text] [Related]
29. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
30. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
Prabu A; Hassan S; Prabuseenivasan ; Shainaba AS; Hanna LE; Kumar V
J Mol Graph Model; 2015 Sep; 61():133-40. PubMed ID: 26245695
[TBL] [Abstract][Full Text] [Related]
31. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
32. Sequence-specific 1H and 15N resonance assignments and secondary structure of GDP-bound human c-Ha-Ras protein in solution.
Muto Y; Yamasaki K; Ito Y; Yajima S; Masaki H; Uozumi T; Wälchli M; Nishimura S; Miyazawa T; Yokoyama S
J Biomol NMR; 1993 Mar; 3(2):165-84. PubMed ID: 8477185
[TBL] [Abstract][Full Text] [Related]
33. Prediction of the relationship between the structural features of andrographolide derivatives and α-glucosidase inhibitory activity: a quantitative structure-activity relationship (QSAR) study.
Moorthy NS; Ramos MJ; Fernandes PA
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):78-87. PubMed ID: 21171896
[TBL] [Abstract][Full Text] [Related]
34. DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.
Majrashi TA; Sabt A; Almahli H; El Hassab MA; Noamaan MA; Elkaeed EB; Hamissa MF; Maslamani AN; Shaldam MA; Eldehna WM
PLoS One; 2024; 19(3):e0300035. PubMed ID: 38457483
[TBL] [Abstract][Full Text] [Related]
35. Investigation of the binding of a carbohydrate-mimetic peptide to its complementary anticarbohydrate antibody by STD-NMR spectroscopy and molecular-dynamics simulations.
Szczepina MG; Bleile DW; Pinto BM
Chemistry; 2011 Oct; 17(41):11446-55. PubMed ID: 21953925
[TBL] [Abstract][Full Text] [Related]
36. Molecular interaction between K-Ras and H-REV107 in the Ras signaling pathway.
Han CW; Jeong MS; Jang SB
Biochem Biophys Res Commun; 2017 Sep; 491(2):257-264. PubMed ID: 28743497
[TBL] [Abstract][Full Text] [Related]
37. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
38. Comparison of ras-p21 bound to GDP and GTP: differences in protein and ligand dynamics.
Mello LV; van Aalten DM; Findlay JB
Protein Eng; 1997 Apr; 10(4):381-7. PubMed ID: 9194162
[TBL] [Abstract][Full Text] [Related]
39. Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein.
Hőgye F; Farkas LB; Balogh ÁK; Szilágyi L; Alnukari S; Bajza I; Borbás A; Fehér K; Illyés TZ; Timári I
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339036
[TBL] [Abstract][Full Text] [Related]
40. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
Mor A; Keren G; Kloog Y; George J
Eur J Immunol; 2008 Jun; 38(6):1493-502. PubMed ID: 18461565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
